SuzanneLouiseTopalianMD
General Surgery • Baltimore, MDSurgical Oncology (Other than Breast)
Professor of Surgery, Professor of Oncology, Johns Hopkins University School of Medicine; Melanoma Program Director
Are you Dr. Topalian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 62 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Baltimore, MD 21287
Summary
- Dr. Suzanne Topalian, MD is a general surgeon in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland and Pennsylvania. She is affiliated with Johns Hopkins Hospital and Johns Hopkins Howard County Medical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989- Clinical Center at the National Institutes of HealthResidency, Surgery, 1985 - 1986
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Surgery, 1983 - 1985
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Surgery, 1982 - 1983- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Surgery, 1979 - 1982
Tufts University School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 2006 - 2025
PA State Medical License 1981 - 2014
Clinical Trials
- Vaccine Therapy in Treating Patients With Metastatic Melanoma Start of enrollment: 1999 Jul 01
- Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Start of enrollment: 2003 Jan 01
Publications & Presentations
PubMed
- Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.Tracee L McMiller, Sepideh Besharati, Mark Yarchoan, Qingfeng Zhu, Keziban Ünsal-Kaçmaz
Journal for Immunotherapy of Cancer. 2024-11-20 - Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao
Journal of Clinical Oncology. 2024-11-06 - 7 citationsNivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese
The Lancet. Oncology. 2024-05-01
Press Mentions
Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023- Hopkins Immunotherapy Researchers Named Fellows of the SITC Academy of Immuno-OncologySeptember 19th, 2022
- Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer and Also Strengthens Scientific Advisory BoardNovember 24th, 2020
- Join now to see all
Grant Support
- Recognition Of Self And Mutated Self By Autoimmune And Tumor-Specific TcrsNational Institute Of Allergy And Infectious Diseases2010–2011
- B7-H1/Pd-1 Modulation In Cancer TherapyNational Cancer Institute2010–2011
- Recognition Of Self And Mutated Self By Autoimmune And Tumor-Specific TcrsNational Institute Of Allergy And Infectious Diseases2008–2009
Other Languages
- French
